AIM
NBIX icon

Ada Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

Ada Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		$271K Buy
+4,793
New +$244K 0.18% 232

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ada Investment Management's NBIX Position: Q4 2015 in Review

Ada Investment Management opened a new position in Neurocrine Biosciences (NBIX) in Q4 2015: 4,793 shares worth $271K. The stake represents 0.18% of the portfolio and ranks #232 among its holdings.

218 funds tracked by Wall St. Rank hold NBIX as of Q4 2015.

  • Ada Investment Management held 4,793 shares of Neurocrine Biosciences worth $271K as of Q4 2015.
  • Neurocrine Biosciences was a new Ada Investment Management position in Q4 2015.
  • Neurocrine Biosciences made up 0.18% of Ada Investment Management's portfolio in Q4 2015, its #232 holding.
  • 218 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2015.

Based on Ada Investment Management's 13F filing for Q4 2015, filed 19 Feb 2016.